Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is already responsible for
far more deaths than previous pathogenic coronaviruses (CoVs) from 2002 and 2012. The …

Background The pandemic caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has resulted in millions of infections worldwide. While the search for an …

In 2003, the screening of approved drugs identified lopinavir, the inhibitor of HIV type 1
aspartate protease, as a potential treatment of severe acute respiratory syndrome (SARS) …

Objectives Given the high need and the absence of specific antivirals for treatment of COVID-
19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 …

In parallel with vaccination, oral antiviral agents are highly anticipated to act as
countermeasures for the treatment of the coronavirus disease 2019 (COVID-19) pandemic …

COVID-19 caused by SARS-CoV-2 has continually been serious threat to public health
worldwide. While a few anti-SARS-CoV-2 therapeutics are currently available, their antiviral …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appeared in 2019 and is
the causative agent of the new pandemic viral disease COVID-19. The outbreak of COVID …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection continues to be a
serious global public health threat. The 3C-like protease (3CLpro) is a virus protease …

Effective control of COVID-19 requires antivirals directed against SARS-CoV-2. We
assessed 10 hepatitis C virus (HCV) protease-inhibitor drugs as potential SARS-CoV-2 …

Severe acute respiratory syndrome virus 2 (SARS-CoV-2) is the cause of the current
coronavirus disease 19 (COVID-19) pandemic. Protease inhibitors are under consideration …